Results 51 to 60 of about 2,583,563 (290)

Combination With Tomatidine Improves the Potency of Posaconazole Against Trypanosoma cruzi

Frontiers in Cellular and Infection Microbiology, 2021
Azoles such as posaconazole (Posa) are highly potent against Trypanosoma cruzi. However, when tested in chronic Chagas disease patients, a high rate of relapse after Posa treatment was observed. It appears that inhibition of T.
Marianne Rocha-Hasler, Marianne Rocha-Hasler, Marianne Rocha-Hasler, Gabriel Melo de Oliveira, Aline Nefertiti da Gama, Ludmila Ferreira de Almeida Fiuza, Anna Frieda Fesser, Anna Frieda Fesser, Monica Cal, Monica Cal, Romina Rocchetti, Romina Rocchetti, Raiza Brandão Peres, Xue Li Guan, Marcel Kaiser, Marcel Kaiser, Maria de Nazaré Correia Soeiro, Pascal Mäser, Pascal Mäser   +18 more
doaj   +1 more source

Optimized Treatment Schedules for Chronic Myeloid Leukemia

, 2016
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David, Foo, Jasmine, He, Qie, Leder, Kevin, Zhu, Junfeng   +4 more
core   +3 more sources

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Primary lung carcinomas and bronchial carcinoid tumors (BC) are very rare malignancies in childhood. While typical BC and mucoepidermoid carcinomas are mostly low‐grade, localized tumors with a more favorable prognosis than in adults, necessitating avoidance of overtreatment, adenocarcinomas of the lung are often diagnosed at advanced disease ...
Michael Abele, Calogero Virgone, Michaela Kuhlen, Sabine Irtan, Yves Reguerre, Malgorzata Krawczyk, Ewa Bien, Tal Ben‐Ami, Maja Cesen, Ricardo Lopez‐Almaraz, Andrea Ferrari, Gianni Bisogno, Dominik T. Schneider, Abbas Agaimy, Constantin Lapa, Hubert Ducou le Pointe, Rainer Claus, Catherine Daniel, Ines B. Brecht, Daniel Orbach   +19 more
wiley   +1 more source

A proteomic landscape of pharmacologic perturbations for functional relevance

Journal of Pharmaceutical Analysis
Pharmacological perturbation studies based on protein-level signatures are fundamental for drug discovery. In the present study, we used a mass spectrometry (MS)-based proteomic platform to profile the whole proteome of the breast cancer MCF7 cell line ...
Zhiwei Liu, Shangwen Jiang, Bingbing Hao, Shuyu Xie, Yingluo Liu, Yuqi Huang, Heng Xu, Cheng Luo, Min Huang, Minjia Tan, Jun-Yu Xu   +10 more
doaj   +1 more source

Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya, Veronica Moroz, Juliet Hale, Vesna Pavasovic, Rachel Hobson, Patricia Sartori, Daniel Saunders, Mark Powis, Gordan M. Vujanic, Stephen Baker, Kathy Pritchard‐Jones   +10 more
wiley   +1 more source

Ibuprofen-loaded calcium phosphate granules : combination of innovative characterization methods to relate mechanical strength to drug location [PDF]

, 2010
This paper studies the impact of the location of a drug substance on the physicochemical and mechanical properties of two types of calcium phosphate granules loaded with seven different contents of ibuprofen, ranging from 1.75% to 46%.
Ahola, Ayers, Bohner, Brunauer, Charnay, Chevalier, Chevalier, Corry, Costa, D. Chulia, Daculsi, Daculsi, De Peinder, Dubois, E. Chevalier, Fernandez-Carballido, Gabaude, Ginebra, Hasegawa, Hiestand, Huber, Hulbert, J. Dubois, L. Makein, Ladrón de Guevara-Fernández, Lawn, LeGeros, Li, M. Viana, Marchi, Melville, Mendez, Otsuka, Passuti, Pitchumani, Quinn, Ruotsalainen, Räsänen, S. Cazalbou, Sivakumar, Uchida, Vallet-Regí, Viana, Yang, Zeitler   +44 more
core   +3 more sources

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

PolyLLM: polypharmacy side effect prediction via LLM-based SMILES encodings

Frontiers in Pharmacology
Polypharmacy, the concurrent use of multiple drugs, is a common approach to treating patients with complex diseases or multiple conditions. Although consuming a combination of drugs can be beneficial in some cases, it can lead to unintended drug-drug ...
Sadra Hakim, Alioune Ngom
doaj   +1 more source

PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases

Frontiers in Molecular Biosciences, 2022
Drug combinations can increase the therapeutic effect by reducing the level of toxicity and the occurrence of drug resistance. Therefore, several drug combinations are often used in the management of complex diseases.
Yongkai Hong, Dantian Chen, Yaqing Jin, Mian Zu, Yin Zhang   +4 more
doaj   +1 more source